When was NChroma Bio founded?

NChroma Bio was founded in 2024.

Where is NChroma Bio located?

NChroma Bio is located in San Diego, United States .

Where does NChroma Bio rank among its competitors?

NChroma Bio ranks 240 amongst 243 active competitors.

Who are the top competitors of NChroma Bio?

NChroma Bio's top competitors are Senti Biosciences, Beam Therapeutics and eGenesis.

NChroma Bio - 2025 Company Profile & Competitors - Tracxn

NChroma Bio is an unfunded company based in San Diego (United States), founded in 2024. It operates as a Developer of cargo and targeted in vivo delivery technologies for genetic medicine. NChroma Bio has not raised any funding yet. The company has 243 active competitors, including 107 funded and 32 that have exited. Its top competitors include companies like Senti Biosciences, Beam Therapeutics and eGenesis.

Company Details

Developer of cargo and targeted in vivo delivery technologies for genetic medicine. It offers a lead program CRMA-1001 which is a liver-targeted epigenetic editing therapy with potential for potency and ability to drive functional cures for chronic hepatitis B and hepatitis D.

Key Metrics

Founded Year

2024

Location

San Diego, United States

Stage

Unfunded

Ranked

240^th among 243 active competitors

Similar Companies

Senti Biosciences & 281 more

NChroma Bio has not raised any funding rounds yet.

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of NChroma Bio include Senti Biosciences, Beam Therapeutics and eGenesis. Here is the list of Top 10 competitors of NChroma Bio, ranked by Tracxn score:

Overall Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Senti Biosciences 2016, San Francisco (United States), Public	Developer of cell-based therapies for cancer treatment	$158M	Ridgeback Capital Management, Omega Funds & 30 others	72/100
2nd	Beam Therapeutics 2017, Cambridge (United States), Public	Developer of gene therapy using CRISPR base editing to treat diseases	$222M	BB Biotech, HTIF & 16 others	69/100
3rd	eGenesis 2015, Cambridge (United States), Series D	Developer of a gene transplantation platform for humanizing pig cells	$481M	Alta Partners, HBM Healthcare Investments & 30 others	68/100
4th	Tessera Therapeutics 2017, Cambridge (United States), Series C	Provider of new genome engineering technology for treating multiple diseases	$610M	Foresite Capital, T. Rowe Price & 22 others	64/100
5th	Korro Bio 2018, Cambridge (United States), Public	Provider of RNA-editing technologies for precision medicine	$4M	Citadel, New Enterprise Associates & 13 others	63/100
6th	Tenaya Therapeutics 2016, San Francisco (United States), Public	Developer of regenerative and gene therapeutics for heart failure	$248M	Greenspring Associates, RA Capital Management & 7 others	61/100
7th	Eiger BioPharmaceuticals 2000, San Carlos (United States), Public	Developer of antiviral agents against targets in the treatment of hepatitis	$8.9M	Tekla Capital Management, InterWest Partners & 9 others	59/100
8th	Metagenomi 2016, Berkeley (United States), Public	Digital gene editing technologies for drug development	$376M	Frazier Healthcare Partners, PFM Health Sciences & 22 others	59/100
9th	Rejuvenate Bio 2017, San Diego (United States), Series A	Developer of a gene-editing platform and anti-aging therapy for dogs	$14.6M	VCapital, Companion Fund & 6 others	59/100
10th	Locus Biosciences 2015, Raleigh (United States), Series B	Developer of therapeutics for infectious disease and inflammatory indications	$67.3M	Hercules Capital, Viking Global Investors & 13 others	58/100
240th	NChroma Bio 2024, San Diego (United States), Unfunded	Developer of cargo and targeted in vivo delivery technologies for genetic medicine	-	-	14/100